SPRING BANK PHARMACEUTICALS, INC. (NASDAQ:SBPH) Files An 8-K Results of Operations and Financial Condition

SPRING BANK PHARMACEUTICALS, INC. (NASDAQ:SBPH) Files An 8-K Results of Operations and Financial Condition
Item 2.02Results of Operations and Financial Condition.

Story continues below

On April 27, 2018, Spring Bank Pharmaceuticals, Inc. issued a press release announcing its financial results for the first quarter ended March 31, 2018. A copy of the press release is furnished as Exhibit 99.1 hereto.

The information contained in this Item, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for any purpose, and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, regardless of any general incorporation language in any such filing.

Item 9.01Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.



Press Release issued April 27, 2018.

Spring Bank Pharmaceuticals, Inc. Exhibit
EX-99.1 2 sbph-ex991_7.htm EX-99.1 sbph-ex991_7.htm Exhibit 99.1   Spring Bank Pharmaceuticals Provides Corporate Update and Reports First Quarter Financial and Operational Results   Presented inarigivir 25 mg and 50mg cohorts from Phase 2 ACHIEVE trial in chronic hepatitis B patients at two scientific conferences Continues to advance SB 11285,…
To view the full exhibit click here


Spring Bank Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of a class of therapeutics using its small molecule nucleic acid hybrid (SMNH) chemistry platform. The Company is developing its SMNH product, SB 9200, for the treatment of viral diseases. The Company’s SB 9200 selectively activates within infected cells the cellular proteins retinoic acid-inducible gene 1 (RIG-I) and nucleotide-binding oligomerization domain-containing protein 2 (NOD2) to inhibit viral replication and to cause the induction of intracellular interferon signaling pathways for antiviral defense. It also focuses on the use of SB 9200 in other viral diseases, including respiratory syncytial virus (RSV), human immunodeficiency virus (HIV), and latency and hepatitis delta virus (HDV), conducting preclinical research of additional SMNH product candidates or compounds as antiviral therapies and conducting early-stage research programs.

An ad to help with our costs